CopyPastehas never been so tasty!

Parasitic Partnering 2007-2012

by anonymous

  • 0
  • 0
  • 0
65 views

Summary

The Parasitic Partnering 2007-2012 report provides understanding and access to the parasitic partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in parasitic partnering deals
Top parasitic deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
Description http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/parasitic-partnering-2007-2012.html

The Parasitic Partnering 2007-2012 provides understanding and access to the parasitic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of parasitic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors parasitic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner?s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases do not.

This data driven report contains over 40 links to online copies of actual parasitic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner?s flexibility on a wide range of important issues, many of which will have a significant impact on each party?s ability to derive value from the deal.

The initial chapters of this report provide an orientation of parasitic partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in parasitic partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading parasitic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of parasitic partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of parasitic technologies and products.

Report scope

Parasitic Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to parasitic trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in parasitic dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
The leading parasitic deals by value since 2007
In Parasitic Partnering 2007-2012, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits
Parasitic Partnering 2007-2012 provides the reader with the following key benefits:


In-depth understanding of parasitic deal trends since 2007
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 40 actual parasitic deals entered into by the world?s biopharma companies since 2007
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 ? Introduction

Chapter 2 ? Trends in parasitic partnering
2.1. Introduction
2.2. Parasitic partnering over the years
2.3. Bigpharma parasitic dealmaking activity
2.4. Parasitic partnering by deal type
2.5. Parasitic partnering industry sector
2.6. Parasitic partnering by stage of development
2.7. Parasitic partnering by technology type
2.8. Disclosed financial deal terms for parasitic partnering
2.8.1 Parasitic headline values
2.8.2 Parasitic upfront payments
2.8.3 Parasitic milestone payments
2.8.4 Parasitic royalty rates

Chapter 3 ? Leading parasitic deals
3.1. Introduction
3.2. Top parasitic deals by value
3.3. Top parasitic deals involving bigpharma

Chapter 4 ? Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines

Chapter 5 ? Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices
Appendix 1 ? Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form ? Reports

Table of Figures
Figure 1: Parasitic partnering since 2007
Figure 2: Bigpharma ? top 50 ? parasitic deals 2007 to 2011
Figure 3: Bigpharma parasitic deal frequency ? 2007 to 2011
Figure 4: Parasitic partnering by deal type since 2007
Figure 5: Parasitic partnering by industry sector since 2007
Figure 6: Parasitic partnering by stage of development since 2007
Figure 7: Parasitic partnering by technology type since 2007
Figure 8: Parasitic deals with a headline value
Figure 9: Parasitic deals with upfront payment values
Figure 10: Parasitic deals with milestone payments
Figure 11: Parasitic deals with royalty rates, %
Figure 12: Top parasitic deals by value since 2007
Figure 13: Top parasitic deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

For more information kindly visit :
Parasitic Partnering 2007-2012

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/

Add A Comment: